Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Clear out junk files and repair common Windows errorsFree Scan →iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
A 2005 laboratory study showed a way to assemble targeted delivery complexes from separate components: researchers joined two kinds of PAMAM dendrimers with complementary DNA strands, then observed fluorescent complexes entering cancer cells reported to have many folic acid receptors. The result demonstrated a cell-level proof of feasibility—not a drug treatment, human trial, or established clinical technology.
What the researchers assembled
Dendrimers are synthetic, tree-like macromolecules with chains radiating from a central atom or cluster of atoms. The University of Michigan, Ann Arbor team led by James Baker used polyamidoamine (PAMAM) dendrimers, assigning different functions to separate groups rather than attaching several different compounds to one dendrimer.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Molecular Biology of the Cell | $203.99 | Buy on Amazon |
| 2 |
|
Molecular Biology: Principles and Practice | $169.53 | Buy on Amazon |
| 3 |
|
Molecular Biology of the Cell | $160.49 | Buy on Amazon |
| 4 |
|
BRS Biochemistry, Molecular Biology, and Genetics (Board Review Series) | $64.99 | Buy on Amazon |
| 5 |
|
Molecular Cell Biology (842581) | $329.81 | Buy on Amazon |
- One group of dendrimers carried folic acid, intended to provide a targeting component.
- A second group carried a fluorescent compound, which made the complexes visible in the reported cell experiment.
- Each group also carried a complementary DNA strand 34 bases long. When the two groups were mixed, the strands bound together to form a dumbbell-shaped complex, with folic acid at one end and the fluorescent compound at the other.
The distinction mattered because, according to Chemistry World’s 2005 report, attaching multiple different compounds to a single dendrimer had been a difficult process that could take months. The linked-dendrimer approach instead put one compound on each carrier and joined the carriers. The report describes this strategy; it does not present a head-to-head experiment showing that it was faster or more effective.
Free tools Windows power users keep installed
One-click scans. No signup required.
What the cell experiment showed
The report says that cancer cells with many folic acid receptors took up the assembled complexes and fluoresced. That observation supports the feasibility of using folic acid-bearing dendrimers in a cell-level targeting design, while the fluorescent component made uptake observable.
#1 Best Overall
It does not show that a drug was delivered, that the approach treated or slowed cancer, or that it worked in people. The report gives no clinical outcomes, patient population, trial results, or regulatory status. It also does not establish whether the method later entered trials or became commercially available.
What the proposed next step meant
Baker described a possible extension: a nanoparticle cluster in which one dendrimer links to three others, with members carrying a targeting compound, an imaging agent, and a drug. This was an envisioned application, not a result demonstrated in the reported experiment. The cell observation involved folic acid and a fluorescent compound; it did not establish a three-part drug-delivery system.
Rank #2
Baker said, “With this approach, you can target a wide variety of molecules – drugs, contrast (imaging) agents – to almost any cell”. That statement expresses the research team’s ambition, not proof that the approach can target any cell or deliver a working treatment.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Fix the driver behind crashes, sound loss and screen glitches3Repair Windows errors before they cause bigger problemsHow to read the report today
Chemistry World published Jon Evans’s report, “Drug delivery branches out,” on March 1, 2005. It is a report of an early laboratory feasibility experiment, not evidence of a current medical product or standard of care. The account supplies no named population, clinical outcome, or market statistic, so there is no basis here for estimating patient benefit or present-day availability.
Quick Recap
Best Value
Rank #3
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
